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Abstract
Purpose Chemotherapy with platinum compounds and
gemcitabine is frequently used in first-line treatment of
advanced non-small cell lung cancer (NSCLC) patients in
which tyrosine kinase inhibitors (EGFR or ALK) cannot be
administered. Unfortunately, less than half of the patients
achieve the benefit from chemotherapy. Gemcitabine is an
analog of deoxycytidine (pyrimidine antimetabolite) with
antitumor activity. The excess of deoxycytidine synthe-
sized by RRM1 enzyme activity may be a cause of com-
petitive displacement of gemcitabine, which reduces the
efficacy of this cytostatic. The aim of this study was to
determine the association between single nucleotide poly-
morphisms (SNPs) of the RRM1 promoter (-37C[A,
-524C[T) and the effectiveness of first-line chemotherapy
based on platinum compounds and gemcitabine in NSCLC
patients.
Patients and methods SNPs were determined by SNaP-
shot PCR in DNA isolated from peripheral blood of 91
NSCLC patients.
Results The median progression-free survival (PFS) was
significantly longer in carriers of AA (-37C[A) as well as
CC (-524C[T) genotype of RRM1 compared to patients
with other genotypes (10.5 vs 3.5 months, p = 0.0437;
HR = 2.17, 95 % CI 1.02–4.62 and 10.5 vs 3.5 months,
p = 0.0343; HR = 2.12, 95 % CI 1.06–4.27). In addition,
the CC genotype carriers (-37C[A) showed a significant
increase in the risk of shortening overall survival (OS) in
comparison to patients with AA or AC genotypes (9.5 vs
18 months, p = 0.0193; HR = 2.13, 95 % CI 1.13–4.03).
Conclusions Presence of rare AA (-37C[A) and CC
(-524C[T) genotypes of the RRM1 may be favorable
predictive factors for chemotherapy with platinum com-
pounds and gemcitabine in NSCLC patients.
Keywords RRM1  Chemotherapy  Gemcitabine 
Platinum compounds  Non-small cell lung cancer
Introduction
Non-small cell lung cancer (NSCLC, representing approx.
85 % of lung cancer cases) is still the most common cause
of death (1.6 million in 2012) due to malignancies in
developed countries [1]. Despite the dynamic development
of medicine, the chemotherapy based on platinum com-
pounds (cis- or carboplatin) and third generation drugs (e.g.
gemcitabine) still remains standard regimen of the first-line
treatment of advanced NSCLC. After administration of
standard first-line chemotherapy, the objective response
rates (ORR) varies between 20 and 30 %. Chemotherapy
provides slight prolongation of patients’ survival time
(1.5 months compared to the best supportive care, BSC);
however, its use is associated with occurrence of relevant
toxicity. Median overall survival (OS) of patients treated
by systemic therapy range from 6 to 12 months [2]. Iden-
tification of driver mutations or other gene alterations (e.g.
activating mutations in the EGFR and ALK rearrange-
ments), which are potential molecular targets, seems to be
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an important advancement in optimization and individu-
alization of NSCLC therapy. These drugs significantly
improved treatment outcomes (over 60 % ORR, progres-
sion free survival (PFS) prolonged to 10 months) with
acceptable toxicity [3–6]. Only 10–30 % (EGFR muta-
tions) or 3–7 % (ALK rearrangements) Caucasian patients
with advanced non-squamous NSCLC have molecular
alterations and should be treated by target therapy. The
lack of identified molecular targets for squamous cell car-
cinoma treatment is the reason why majority of patients
still receive standard chemotherapy [7–9]. On the other
hand, genetic predisposition (e.g. gene polymorphisms or
mRNA expression) may be used to selection for potentially
the most effective treatment regimens, which can prolong
the life of patients and improve its quality [10–12]. Among
the molecular changes, potentially the highest impact on
the efficacy of chemotherapy have alterations of genes,
which coding proteins involved in drug metabolism.
Gemcitabine is frequently used in the treatment of NSCLC,
ovarian and pancreatic cancer. Its mechanism of action is
based on the incorporation to nucleic acids, which conse-
quently induce apoptosis. The excess of deoxycytidine,
biosynthesized with the participation of RRM1 causes
competitive displacement of gemcitabine, reducing the
efficacy of this chemotherapeutic agent [13, 14]. Some
researchers have demonstrated that in patients with
NSCLC the expression or SNPs of RRM1 may play prog-
nostic and predictive role (e.g. for gemcitabine). The
influence of single nucleotide polymorphisms (SNPs) on
survival and the response to treatment with platinum
compounds and gemcitabine in patients with advanced
NSCLC are still not fully understood. Among the already
known RRM1 SNPs, -37C[A (rs12806698) and
-524C[T (rs11030918) seem to have the greatest impor-
tance as potential predictors of treatment regimens based
on gemcitabine in NSCLC patients [15–17].
The aim of this study was to determine the association
between SNPs of RRM1 promoter (-37C[A, -524C[T)
and the effectiveness of chemotherapy based on platinum
compounds and gemcitabine in patients with inoperable or
advanced NSCLC.
Materials and methods
The study was performed on 91 Caucasian patients with
inoperable, locally advanced or metastatic NSCLC (IIIB
and IV), treated from 2010 to 2013 at the Department of
Pneumonology, Oncology and Allergology, Medical
University of Lublin. NSCLC diagnosis was based on
histopathological or cytological examination. In the first-
line treatment all patients received standard chemotherapy,
Table 1 Patient characteristics
Variable Study group (n = 91)
Sex
Male 61 (67 %)
Female 30 (33 %)
Age (years)
Median 62




Mean ± SD 31.4 ± 9.5
Non-smokers 5 (5.5 %)
Current smokers 65 (71.4 %)
Former Smokers 20 (22 %)
No data 1 (1.1 %)
Histopathological diagnosis
Adenocarcinoma 46 (50.5 %)
Squamous cell carcinoma 14 (15.4 %)
Large cell carcinoma 16 (17.6 %)
NOS (not otherwise specified) 15 (16.5 %)
Stage of disease
IIIB 28 (30.8 %)
IV 63 (69.2 %)
Performance status
PS = 0 12 (13.2 %)
PS C 1 79 (86.8 %)
Weight loss before CTH
Yes 39 (42.9 %)
No 43 (47.2 %)
No data 9 (9.9 %)
Anemia before CTH
Yes 59 (64.8 %)
No 32 (35.2 %)
Side effect after I line CTH
Yes 59 (64.8 %)
No 24 (26.4 %)
No data 8 (8.8 %)
Subsequent lines of treatment
Yes 51 (56.1 %)
No 40 (43.9 %)
Second-line CTH (monotherapy) 51 (56.1 %)
ERL 12 (13.2 %)
PEM 26 (28.6 %)
DCX 13 (14.3 %)
Third-line CTH (monotherapy) 15 (16.5 %)
ERL 5 (5.5 %)
PEM 6 (6.6 %)
DCX 4 (4.4 %)
ERL erlotinib, DCX docetaxel, PEM pemetrexed
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based on platinum compounds and gemcitabine. The stage
of disease was evaluated according to the TNM classifi-
cation (VII edition by UICC). The median number of
cycles of first-line chemotherapy was 4 (range 2–6). Sub-
sequent lines of therapy: second or third were used in 56.1
and 16.5 % of patients, respectively (Table 1). Response to
treatment was evaluated by RECIST V1.1 (Response
Evaluation Criteria in Solid Tumors). Adverse events were
estimated by Common Toxicity Criteria for Adverse
Events (CTCAE) V4.0.
The isolation of DNA from peripheral blood leukocytes
was performed using DNA Blood Mini Kit (Qiagen,
Canada). Quality and quantity of extracted DNA were
measured using a spectrophotometer BioPhotometer plus in
cuvette equipped with UV/VIS filters (Eppendorf, Ger-
many). Analysis of SNPs was conducted using the mini-
sequencing technique (SNaPshot PCR). For the reaction,
a set of ABI PRISM SNaPshot Multiplex (Life Tech-
nologies, USA) was used. An example of the results of
genotyping is shown in Fig. 1.
Statistical analysis
Statistical analysis was done using Statistica 10 (Statsoft,
USA) and MedCalc 10 (MedCalc Software, Belgium). The
results of p\ 0.05 were considered to be statistically
significant. Using the Chi-Square (v2) balance of the
Hardy–Weinberg (HW) equilibrium, associations between
a series factors with the distribution of RRM1 polymor-
phisms were calculated. The Kaplan–Meier method was
used to draw a comparison curve evaluating the survival
probability (PFS and OS). Cox regression model with a
stepwise selection with minimum AIC factor (Akaike
Information Criterion) was used to determine the influence
of clinical and genetic factors on survival. The median
survival in the groups was compared by the use of the
U-Mann–Whitney test.
Results
Distributions of genotypes in the RRM1 (-37C[A,
-524C[T) did not depend on factors such as gender, age,
histological type, stage of disease, performance status or
smoking status (Table 2). The distribution of genotypes
within the SNP -524C[T, unlike the -37C[A, was in
Hardy–Weinberg equilibrium (p = 0.0966, v2 = 2.7612
for -524C[T and p = 0.0279, v2 = 4.8336 for
-37C[A). Genotypes AA, AC and CC of RRM1
(-37C[A) occurred respectively in 5.7, 54.5 and 39.8 %
of patients. Genotypes CC, CT and TT of RRM1
(-524C[T) occurred, respectively, in 7.7, 52.7 and 39.6 %
Fig. 1 Example of genotyping
results of RRM1 gene obtained
by capillary electrophoresis of
the SNaPshot PCR products.
From left (-37C[A and
-524C[T respectively): AC
and TT heterozygotes, CC and
TT homozygotes
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of patients. Due to the fact that studied SNPs are located in
the same gene (on chromosome 11) using the online tool
SNAP (Broad Institute, USA) and data from the Interna-
tional HapMap project assesses coupling allele linkage
disequilibrium (LD), LD was calculated based on data from
population-based genetic studies (Utah state residents
whose ancestors came from the north-western regions of
Europe–CEU). Analyzed pair of SNPs has not reached the
correlation coefficient R2[ 0.8 so, we concluded that they
do not create haplotypes and are not subject to the common
inheritance.
Response to chemotherapy
There were no cases of complete remission (CR) as a result
of first-line chemotherapy with platinum compounds and
gemcitabine. Control of the disease was observed in
54.9 % of patients, of which partial remission (PR) and
stable disease (SD) occurred, respectively, in 17.6 and
37.3 % of patients. Disease progression (PD) was observed
in 45.1 % of patients. Patients with squamous cell carci-
noma or those who develop anemia before chemotherapy
had a significantly lower chance of disease control
(p = 0.0392, OR = 0.27; p = 0.0189, OR = 0.33,
respectively) when compared to other patients. Moreover,
in patients with poor performance status (PS = 1) the risk
of PD (p = 0.0495, OR = 4.87) was higher. There were no
statistically significant differences in response according to
other demographic and clinical factors. Both SNPs:
-37C[A and -524C[T of RRM1 did not affect signifi-
cantly the possibility of responses to treatment. In logistic
regression analysis (including: sex, age, histopathological
diagnosis, stage of disease, PS and SNPs of RRM1; overall
fit of the model: v2 = 22.45, p = 0.0021) only PS
(p = 0.0002, OR = 0.0849 95 % CI 0.02–0.31) had an
independent influence on ORR. Effect of SNPs of RRM1
was insignificant, however, the CC genotype (-37C[A)
show a trend towards significance (p = 0.0655).
Progression-free survival
The median PFS of whole group of patients was 4 months.
In patients who were diagnosed with adenocarcinoma or
non-squamous cell carcinoma compared to squamous cell
carcinoma patients a significantly lower risk of shortening
PFS was noticed (respectively, 6 vs 3 months, p = 0.0456,
HR = 0.61, 95 % CI 0.37–0.99 and 4.5 vs 2 months,
p = 0.0140, HR = 0.34, 95 % CI 0.14–0.80). In patients
with IIIB stage of NSCLC and patients without anemia
compared to other patients, the risk of shortening of PFS
was significantly lower (respectively, 7 vs 3, p = 0.0094,
HR = 0.52, 95 % CI 0.32–0.85; 6.5 vs 3 months,
p = 0.0154, HR = 0.54, 95 % CI 0.33–0.89). Other fac-
tors did not affect PFS significantly.
Carriers of the C allele of the RRM1 (-37C[A) showed
a significant increase in the risk of PFS shortening in
comparison to patients with the AA genotype (3.5 vs
10.5 months, p = 0.0437; HR = 2.17, 95 % CI 1.02–4.62,
Fig. 2). Similarly, the presence of the T allele of RRM1
(-524C[T) was associated with a significant risk of
shortening of PFS when confronted with the CC genotype
carriers (3.5 vs 10.5 months, p = 0.0437; HR = 2.12,
95 % CI 1.06–4.27, Fig. 3).
In a Cox multivariate logistic regression analysis, poor
(PS = 1) performance status (p = 0.0117, HR = 2.75,
95 % CI 1.26–6.02) and anemia prior to treatment
(p = 0.0128, HR = 2.67, 95 % CI 1.24–5.74) were
Fig. 2 The probability of progression-free survival change depending
on RRM1 genotype (-37C[A)
Fig. 3 The probability of progression-free survival change depending
on RRM1 genotype (-524C[T)
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independently responsible for shortening of PFS in patients
treated with chemotherapy using platinum compounds and
gemcitabine (overall fit of the model: p = 0.0271,
v2 = 24.466) (Table 3).
Overall survival
The median OS in the study population was 12 months.
The median OS was significantly longer in patients without
weight loss prior to chemotherapy compared to other
patients (respectively, 18 vs 7.5 months, p = 0.0376;
HR = 0.46, 95 % CI 0.22–0.96). Patients who were treated
with subsequent lines of treatment showed significantly
longer OS than patients who received only one line of
treatment (16.5 vs 8 months, p = 0.0305; HR = 0.50,
95 % CI 0.27–0.94). However, when compared separately
none of second-line scheme has not improve survival sig-
nificantly (ERL vs other 11.5 vs 10 mo.; p = 0.4270,
HR = 1.37, 95 % CI 0.63–2.99; PEM vs other 13 vs 11
mo.; p = 0.1813, HR = 1.51, 95 % CI 0.82–2.76; DCX vs
other 16.5 vs 12 mo.; p = 0.3365, HR = 0.67, 95 % CI
0.29–1.52). There was no statistically significant effect of
other factors on the OS.
The CC genotype carriers of RRM1 (-37C[A) showed
a significant increase in the risk of shortening of OS
compared to patients with AA or AC genotypes (9.5 vs
18 months, p = 0.0193; HR = 2.13, 95 % CI 1.13–4.03,
Fig. 4). None of the SNP -524C[T variants did signifi-
cantly affect the length of OS in the study group (e.g. CC
vs CT or TT, 18.5 vs 11 months, p = 0.5983, HR = 1.29,
95 % CI 0.50–3.30; Fig. 5).
Poor performance status (PS = 1, p = 0.0053,
HR = 5.81, 95 % CI 1.70–19.93) and lack of subsequent
lines of treatment (p = 0.0246, HR = 2.58, 95 % CI
1.15–7.53) were only factors that shorten OS in a Cox
multivariate logistic regression analysis (overall fit of the
model v2 = 27.73, p = 0.0233).
Discussion
Despite progress in medicine, that has been made in recent
years, there are still lack of predictive factors, which would
allow qualify NSCLC patients to appropriate chemother-
apy regimen. The current criteria of patients’ selection to
cytostatic-based therapy are primarily performance status,
treatment toxicity and clinician’s experience; however, it
seems to be insufficient. In addition, most of the currently
available chemotherapy regimens, regardless of the line of
treatment, are characterized by significant differences in
the effectiveness in various patients. This is another evi-
dence that key to prediction of occurrence of resistance to
cytostatics may be stored in genetic information [10–12,
18, 19].
Reliable evaluation of mRNA or protein expression
requires access to the tumor tissue Tumor tissue in an
advanced stages of NSCLC is difficult or, sometimes,
impossible to obtain. Changes in the structure, function,
stability, folding or expression of proteins may be caused
by occurrence of specific SNPs in encoding or non-coding
sequences (especially located in promoter region) of genes.
Moreover, the analysis of SNPs may be carried out in
materials that are easy to obtain (e.g. DNA from peripheral
blood leukocytes) and thus easier introduced into routine
clinical practice. Consequently, many studies (unfortu-
nately mainly retrospective) assessed the effect of the
individual polymorphic variants of different genes on the
effectiveness of various treatment regimens.
There is lack of meta-analysis evaluating the impact of
any RRM1 SNPs on response to treatment, PFS or OS in
Fig. 4 The probability of overall survival change depending on
RRM1 genotype (-37C[A)
Fig. 5 The probability of overall survival change depending on
RRM1 genotype (-524C[T)
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patients with NSCLC treated with gemcitabine. Among the
eight original papers investigating relationship of SNPs
(-37C[A and/or -524C[T) with response to treatment,
four of them concerned Asian patients. Feng et al. analyzed
both mentioned SNPs (genotypes) independently and in
combination in 214 patients treated with different schemes
chemotherapy based on platinum. Kim et al. evaluated
allelotype of two mentioned SNPs in 97 patients received
chemotherapy based on gemcitabine. Lin et al. estimated
only relationship between -37C[A polymorphism and
effectiveness of chemotherapy regimens containing gemc-
itabine in 40 NSCLC patients. Dong et al. assessed SNPs in
56 patients treated with chemotherapy based on gemc-
itabine [16, 17, 20, 21]. In studies concerning Caucasian
population, analysis of -37C[A SNP was presented by
Isla et al. (62 patients received platinum compounds in
combination with docetaxel), Vinolas et al. (94 patients
treated with platinum compounds in combination with
vinorelbine) and Mlak et al. (62 patients treated with
platinum compounds in combination with gemcitabine).
While, Ludovini et al. assessed -524C[T SNPs in 168
patients received platinum-based chemotherapy [22–25].
Feng and co-workers did not demonstrate the associa-
tion between the -37C[A SNP and the response to
chemotherapy. However, the statistically significant rela-
tionship between -524C[T SNP of RRM1 and response to
treatment (v2 = 6.179, p = 0.046) was proved [16]. In
contrast, Kim et al. reported a significantly higher response
rate in patients with genotype AC/CT (-37C[A/-524C
[T) in comparison to carriers of other combinations of
RRM1 allelotypes (65.5 vs 42.6 %, p = 0.039) [18]. Lin
et al. and Dong et al. have shown no significant differences
in response to treatment depending on the RRM1 genotype
[17, 19]. Isla et al., Vinolas et al., Ludovini et al. demon-
strated no correlation between the genotype of RRM1 and
response to the treatment [23–25].
The only evidence for association of -37A[C poly-
morphism and response to gemcitabine-based chemother-
apy was reported in our previous study. We indicated that
AC genotype was significantly related with less frequent
response to chemotherapy (v2 = 5.47, p = 0.0193). It was
probably caused by the influence of A allele (importance of
AA genotype was impossible to assess due to small study
group). In addition, this study showed a significant asso-
ciation between the presence of genotype AA or AC and
early progression of the disease (v2 = 3.61; p = 0.0573)
[22].
In the available literature six studies describe the rela-
tionship between SNPs of RRM1 and the duration of the
PFS (Dong et al., Mlak et al., Vinolas et al., Isla et al., Kim
et al., Ludovini et al.) and OS (Ryu et al., Mlak et al.,
Vinolas et al., Isla et al., Kim et al., Ludovini et al.) in
patients with NSCLC treated in the first-line with platinum
and third generation drug scheme (usually gemcitabine)
[16, 20, 22–26]. Dong et al. presented the positive study
regarding the impact of RRM1 SNPs on the length of PFS.
Authors demonstrated significant differences in the PFS
depending on -37C[A SNP (23.3, 30.7, 24.7 weeks for
Asian patients with CC, CA, AA genotype, respectively,
p = 0.043) [17]. Among the studies concerning Caucasian
patients, only in our previous publication the presence of a
significant effect of CC genotype (-37C[A) on reduction
of the risk of shortening both PFS (6 months for patients
with CC genotype vs 2 months for others patients,
HR = 0.51, 95 % CI 0.29–0.89, p = 0.0087) and OS
(16.5 months for patients with CC and 8 months for
patients CA or AA genotypes, HR = 0.47; 95 % CI
0.22–0.99, p = 0.0448) was demonstrated [22]. Other
studies revealed no significant association between poly-
morphic variants of RRM1 (-37C[A and/or -524C[T)
and the length of PFS and/or OS in patients with NSCLC
treated with first-line chemotherapy.
Therefore, statistically significant relationship between
-524C[T SNP of RRM1 and the PFS length (CC genotype
was significantly associated with prolongation of PFS) in
patients with advanced NSCLC who were treated first-line
chemotherapy based on platinum compounds and gemc-
itabine was described for the first time in present study. We
also verified the results of the impact of -37C[A SNP on
the PFS (AA genotype was significantly associated with
PFS prolongation) and OS (CC genotype was significantly
associated with OS shortening), described previously in
smaller populations of NSCLC [17, 22]. The limitations of
our research are retrospective character of analysis and
heterogeneous study group.
Unfortunately, despite growing evidence suggesting that
SNPs in genes encoding proteins involved in drug metabo-
lism and DNA repair may help to explain the inter-indi-
vidual variability of response or resistance to chemotherapy,
most of available studies present conflicting results.
Differences between studies may be due to: (1) race
differences (Asian vs Caucasian patients), which are
reflected both in the incidence of SNPs and in phenotypic
disparity; (2) NSCLC has many subtypes (characterized by,
e.g.: differences in driver mutations occurrence and clinical
course) thus in most studies different proportion of each
subtype may occur. Differences in course of treatment: in
some studies; (3) part of patients received chemoradiation.
In first-line regimens different platinum compound (cis- or
carboplatin) may be used; (4) In subsequent lines most
patients are treated with multiple drugs, including: peme-
trexed, docetaxel, and an TKI, as well as may undergo
surgery, which significantly affects course of disease and
survival.
Accordingly, it is crucial to conduct a large randomized
prospective studies taking into account the respective
Clin Transl Oncol (2016) 18:915–924 923
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proportions of race, subtypes of NSCLC, as well as based
on suitable standards and uniform regimens of treatment.
Conclusions
The presence of rare genotypes: AA (-37C[A) and CC
(-524C[T) of RRM1 promoter are favorable predictors
associated with prolongation of PFS in NSCLC patients
treated with first-line chemotherapy with platinum com-
pounds and gemcitabine. Moreover, occurrence of CC
genotype (-37C[A) is unfavorable predictor of OS
shortening. Evaluation of selected SNPs of RRM1 may in
the future, become a useful tool in the qualification of
patients with NSCLC to the appropriate chemotherapy
regimen. However, our results should be previously con-
firmed in sufficiently large and prospective studies.
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